(Reuters) - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement. Financial details were not disclosed. The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug. The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment